Silence Therapeutics’ (SLN) “Outperform” Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report released on Tuesday,RTT News reports.

Several other brokerages have also recently weighed in on SLN. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. Morgan Stanley restated an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, November 15th. Finally, Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Stock Performance

NASDAQ SLN opened at $6.97 on Tuesday. The stock has a market capitalization of $208.60 million, a P/E ratio of -4.44 and a beta of 1.30. Silence Therapeutics has a 52 week low of $6.31 and a 52 week high of $27.72. The stock has a fifty day moving average of $17.58 and a 200-day moving average of $18.94.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds have recently bought and sold shares of SLN. Values First Advisors Inc. bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $56,000. Quarry LP acquired a new position in Silence Therapeutics in the second quarter valued at about $114,000. SG Americas Securities LLC increased its holdings in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after acquiring an additional 667 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics during the third quarter worth about $207,000. Finally, Custom Index Systems LLC bought a new position in shares of Silence Therapeutics during the 2nd quarter valued at about $282,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.